Clinical Trials Browser

Withdrawn × tenalisib × Lymphoid × Clear all

NCT05239910 2022-10-17

Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL

Phase 2 Withdrawn

Lymphoma, T-Cell, Peripheral